ANTI-EGFRVIII ANTIBODY, POLYPEPTIDE, CELL CAPABLE OF EXPRESSING SAID POLYPEPTIDE, PHARMACEUTICAL COMPOSITION CONTAINING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR COMPRISING NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE

Title:

Document Type and Number:

WIPO Patent Application WO/2023/286840

Kind Code:

A1

Abstract:

An anti-EGFRviii antibody that is an antibody having a specific CDR sequence and is selected from the group consisting of the antibodies (a-1) to (a-3); a polypeptide comprising the antibody; a cell capable of expressing the polypeptide; a pharmaceutical composition containing the cell; a method for producing the cell; and a polynucleotide or a vector, which comprises a nucleotide sequence encoding the polypeptide.

More Like This:

JP2019010124	THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOF
JP3387525	FUSED OXIDASE OF CYTOCHROME P450C AND YEAST NADPH-CYTOCHROME PE450 REDUCTASE, GANE ENCODING THE SAME ENZYME AND PRODUCTION OF THE ENZYME
WO/2020/215044	SMALL MOLECULE-BASED CONTROL OF IMMUNE CELL RECEPTOR EXPRESSION

Inventors:

TAMADA KOJI (JP)
SAKODA YUKIMI (JP)
ADACHI KEISHI (JP)

Application Number:

PCT/JP2022/027735

Publication Date:

January 19, 2023

Filing Date:

July 14, 2022

Export Citation:

Click for automatic bibliography generation Help

Assignee:

NOILE IMMUNE BIOTECH INC (JP)

International Classes:

C12N15/62; A61K35/17; A61K38/19; A61K38/20; A61K39/395; A61K47/68; A61K48/00; A61P35/00; A61P37/04; C07K14/54; C07K16/28; C07K19/00; C12N5/0783; C12N5/10; C12N15/11; C12N15/13; C12N15/24

Domestic Patent References:

WO2017159736A1

2017-09-21

Foreign References:

KR101953299B1	2019-02-28
JP2017522884A	2017-08-17
JP2016508725A	2016-03-24
JP2021509105A	2021-03-18
JP6761113B2	2020-09-23

Other References:

ABBOTT REBECCA C, VERDON DANIEL J, GRACEY FIONA M, HUGHES‐PARRY HANNAH E, ILIOPOULOS MELINDA, WATSON KATHERINE A, MULAZZANI MATTHI: "Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma", CLINICAL & TRANSLATIONAL IMMUNOLOGY, JOHN WILEY & SONS LTD, GB, vol. 10, no. 5, 1 January 2021 (2021-01-01), GB , XP093024187, ISSN: 2050-0068, DOI: 10.1002/cti2.1283
JIANG HUA, GAO HUIPING, KONG JUAN, SONG BO, WANG PENG, SHI BIZHI, WANG HUAMAO, LI ZONGHAI: "Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell", CANCER IMMUNOLOGY RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 6, no. 11, 1 November 2018 (2018-11-01), US , pages 1314 - 1326, XP093024188, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-18-0044
L. A. JOHNSON, ET AL: "Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma", SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 275, 18 February 2015 (2015-02-18), pages 1 - 16, XP055362795, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aaa4963
MASASUKE OHNO, ATSUSHI NATSUME, KEN ICHIRO IWAMI, HIDETAKA IWAMIZU, KANA NORITAKE, DAIKI ITO, YUKI TOI, MOTOKAZU ITO, KAZUYA MOTOM: "Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen", CANCER SCIENCE, JAPANESE CANCER ASSOCIATION, vol. 101, no. 12, 30 December 2010 (2010-12-30), pages 2518 - 2524, XP055124889, ISSN: 13479032, DOI: 10.1111/j.1349-7006.2010.01734.x
KABAT, E.A. ET AL.: "Sequences of Proteins of Immunological Interest, US Dept.Health and HumanServices", HUMAN MOST HOMOLOGOUS CONSENSUS SEQUENCE, 1991
"GenBank", Database accession no. NM 001768.6.
TAMADA K ET AL., CLIN CANCER RES, vol. 18, 2012, pages 6436 - 6445

Attorney, Agent or Firm:

TAIYO, NAKAJIMA & KATO (JP)

Download PDF:

View/Download PDF PDF Help

Previous Patent: DEVICE AND PROGRAM FOR CONFIGURING OPERATION OF AUTONOMOUS TRAVELING VEHICLE, STORAGE MEDIUM FOR STO...

Next Patent: CHIMERIC ANTIGEN RECEPTOR, CELL CAPABLE OF EXPRESSING SAID RECEPTOR, PHARMACEUTICAL COMPOSITION CONT...